Y Li1, Y Wang1, S Chubinskaya2, B Schoeberl3, E Florine3, P Kopesky3, A J Grodzinsky4. 1. Massachusetts Institute of Technology, Cambridge, MA, USA. 2. Rush University Medical Center, Chicago, IL, USA. 3. Merrimack Pharmaceuticals, USA. 4. Massachusetts Institute of Technology, Cambridge, MA, USA. Electronic address: alg@mit.edu.
Abstract
OBJECTIVE: Interleukin-1 is one of the inflammatory cytokines elevated after traumatic joint injury that plays a critical role in mediating cartilage tissue degradation, suppressing matrix biosynthesis, and inducing chondrocyte apoptosis, events associated with progression to post-traumatic osteoarthritis (PTOA). We studied the combined use of insulin-like growth factor-1 (IGF-1) and dexamethasone (Dex) to block these multiple degradative effects of cytokine challenge to articular cartilage. METHODS: Young bovine and adult human articular cartilage explants were treated with IL-1α in the presence or absence of IGF-1, Dex, or their combination. Loss of sulfated glycosaminoglycans (sGAG) and collagen were evaluated by the DMMB and hydroxyproline assays, respectively. Matrix biosynthesis was measured via radiolabel incorporation, chondrocyte gene expression by qRT-PCR, and cell viability by fluorescence staining. RESULTS: In young bovine cartilage, the combination of IGF-1 and Dex significantly inhibited the loss of sGAG and collagen, rescued the suppression of matrix biosynthesis, and inhibited the loss of chondrocyte viability caused by IL-1α treatment. In adult human cartilage, only IGF-1 rescued matrix biosynthesis and only Dex inhibited sGAG loss and improved cell viability. Thus, the combination of IGF-1 + Dex together showed combined beneficial effects in human cartilage. CONCLUSIONS: Our findings suggest that the combination of IGF-1 and Dex has greater beneficial effects than either molecule alone in preventing cytokine-mediated cartilage degradation in adult human and young bovine cartilage. Our results support the use of such a combined approach as a potential treatment relevant to early cartilage degradative changes associated with joint injury.
OBJECTIVE:Interleukin-1 is one of the inflammatory cytokines elevated after traumatic joint injury that plays a critical role in mediating cartilage tissue degradation, suppressing matrix biosynthesis, and inducing chondrocyte apoptosis, events associated with progression to post-traumatic osteoarthritis (PTOA). We studied the combined use of insulin-like growth factor-1 (IGF-1) and dexamethasone (Dex) to block these multiple degradative effects of cytokine challenge to articular cartilage. METHODS: Young bovine and adult humanarticular cartilage explants were treated with IL-1α in the presence or absence of IGF-1, Dex, or their combination. Loss of sulfated glycosaminoglycans (sGAG) and collagen were evaluated by the DMMB and hydroxyproline assays, respectively. Matrix biosynthesis was measured via radiolabel incorporation, chondrocyte gene expression by qRT-PCR, and cell viability by fluorescence staining. RESULTS: In young bovinecartilage, the combination of IGF-1 and Dex significantly inhibited the loss of sGAG and collagen, rescued the suppression of matrix biosynthesis, and inhibited the loss of chondrocyte viability caused by IL-1α treatment. In adult humancartilage, only IGF-1 rescued matrix biosynthesis and only Dex inhibited sGAG loss and improved cell viability. Thus, the combination of IGF-1 + Dex together showed combined beneficial effects in humancartilage. CONCLUSIONS: Our findings suggest that the combination of IGF-1 and Dex has greater beneficial effects than either molecule alone in preventing cytokine-mediated cartilage degradation in adult human and young bovinecartilage. Our results support the use of such a combined approach as a potential treatment relevant to early cartilage degradative changes associated with joint injury.
Authors: Jonathan B Fitzgerald; Moonsoo Jin; Delphine Dean; David J Wood; Ming H Zheng; Alan J Grodzinsky Journal: J Biol Chem Date: 2004-02-11 Impact factor: 5.157
Authors: Kodihalli C Ravindra; Caroline C Ahrens; Yang Wang; Julie Y Ramseier; John S Wishnok; Linda G Griffith; Alan J Grodzinsky; Steven R Tannenbaum Journal: J Biol Chem Date: 2018-05-23 Impact factor: 5.157
Authors: Rodolfo E De la Vega; Maximiliano Scheu; Lennart A Brown; Christopher H Evans; Elisabeth Ferreira; Ryan M Porter Journal: Tissue Eng Part C Methods Date: 2019-03 Impact factor: 3.056
Authors: A J Grodzinsky; R M Porter; A G Bajpayee; R E De la Vega; M Scheu; N H Varady; I A Yannatos; L A Brown; Y Krishnan; T J Fitzsimons; P Bhattacharya; E H Frank Journal: Eur Cell Mater Date: 2017-12-05 Impact factor: 3.942
Authors: Brett C Geiger; Sheryl Wang; Robert F Padera; Alan J Grodzinsky; Paula T Hammond Journal: Sci Transl Med Date: 2018-11-28 Impact factor: 17.956